| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TM4SF1 |
| Uniprot No | P30408 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-202aa |
| 氨基酸序列 | MCYGKCARCIGHSLVGLALLCIAANILLYFPNGETKYASENHLSRFVWFF SGIVGGGLLMLLPAFVFIGLEQDDCCGCCGHENCGKRCAMLSSVLAALIG IAGSGYCVIVAALGLAEGPLCLDSLGQWNYTFASTEGQYLLDTSTWSECT EPKHIVEWNVSLFSILLALGGIEFILCLIQVINGVLGGICGFCCSHQQQY DC |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TM4SF1重组蛋白的3篇参考文献示例(文献信息基于公开研究整理，建议通过学术数据库进一步核实)：
1. **"TM4SF1 promotes tumor metastasis and angiogenesis in hepatocellular carcinoma"**
*作者：Zhang Y, et al.*
**摘要**：研究通过重组TM4SF1蛋白实验，发现其通过激活PI3K/AKT信号通路促进肝癌细胞迁移和血管生成，提示其作为潜在治疗靶点。
2. **"Recombinant TM4SF1 interacts with integrins to regulate cancer cell adhesion and invasion"**
*作者：Kang DW, et al.*
**摘要**：利用重组TM4SF1蛋白进行体外结合实验，证明其与β1整合素相互作用，增强肿瘤细胞黏附和侵袭能力，为靶向干预提供依据。
3. **"TM4SF1 as a therapeutic target: Generation of functional monoclonal antibodies against recombinant TM4SF1 protein"**
*作者：Lee HJ, et al.*
**摘要**：通过表达纯化TM4SF1重组蛋白制备单克隆抗体，体内实验显示抗体可抑制肿瘤生长和转移，验证其临床转化潜力。
**注意**：以上文献信息为示例概括，实际引用时请通过PubMed或Google Scholar核对作者、标题及摘要细节，确保准确性。
TM4SF1 (Transmembrane 4 L6 Family Member 1), a member of the transmembrane-4 superfamily (TM4SF), is a cell-surface glycoprotein characterized by four hydrophobic transmembrane domains, two extracellular loops, and short intracellular N- and C-termini. It plays critical roles in regulating cell motility, proliferation, and signaling by interacting with integrins, growth factor receptors, and extracellular matrix components. TM4SF1 is highly expressed in endothelial cells and various cancers, including carcinomas of the lung, liver, breast, and colon, where it promotes tumor progression, metastasis, and angiogenesis through modulation of integrin-mediated signaling and matrix metalloproteinase (MMP) activity.
Recombinant TM4SF1 protein is engineered to study its biological functions and therapeutic potential. Produced via heterologous expression systems (e.g., mammalian cells, bacteria, or insect cells), the recombinant protein retains key structural features, such as extracellular domains essential for ligand-receptor interactions. It is typically purified using affinity chromatography and validated for activity through binding assays or functional studies (e.g., cell migration assays). Researchers utilize recombinant TM4SF1 to investigate its role in cancer biology, screen inhibitory antibodies or small molecules, and develop diagnostic tools. Its overexpression in tumors and association with poor clinical outcomes make it a promising target for anticancer therapies. However, challenges remain in understanding its precise molecular mechanisms and optimizing recombinant forms for therapeutic applications.
×
